Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models

Adila Izgutdina, William C Temple, Matthew Andrew Nix, Huimin Geng, Emilio Ramos, Akul Naik, Rebecca Larson, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Ons Zakraoui, Isa Tariq, Marcela V Maus, Veronica Steri, Arun P Wiita

Blood (2023) 142 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2023-182873

Published: 2023

Journal Articles

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Blood (2023) 142 (Supplement 1): 465.

https://doi.org/10.1182/blood-2023-182578

Published: 2023

Journal Articles

Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo

William C Temple, Gianina Wicaksono, Akul Naik, Adila Izgutdina, Matthew A Nix, Elizabeth Young, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, Fernando Salangsang, Arun P Wiita

Blood (2022) 140 (Supplement 1): 7394–7395.

https://doi.org/10.1182/blood-2022-168490

Published: 2022

Journal Articles

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Blood (2022) 140 (Supplement 1): 867–868.

https://doi.org/10.1182/blood-2022-162697

Published: 2022

Journal Articles

Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Alexis Talbot, Solène Weill, Eléonore Fox, Léa Meunier, Guillaume Appé, Camille Marijon, Abdelkader Behdenna, Arun P Wiita, Akpéli Nordor, Justin Eyquem

Blood (2022) 140 (Supplement 1): 7094–7095.

https://doi.org/10.1182/blood-2022-168403

Published: 2022

Journal Articles

CD72 Nanobody-Based CAR-T Cells Have Potent Anti-Tumor Efficacy in B Cell Malignancies

Matthew A Nix, William C Temple, William Karlon, Donghui Wang, Paul Phojanakong, Veronica Steri, Byron Hann, Arun P Wiita

Blood (2021) 138 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2021-153935

Published: 2021

Journal Articles

Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma

Priya Choudhry, Olivia Gugliemini, Huimin Geng, Vishesh Sarin, Letitia Sarah, Yu-Hsiu T. Lin, Neha Paranjape, Poornima Ramkumar, Makeba Marcoulis, Donghui Wang, Paul Phojanakong, Veronica Steri, Byron Hann, Martin Kampmann, Arun P Wiita

Blood (2021) 138 (Supplement 1): 2648.

https://doi.org/10.1182/blood-2021-147007

Published: 2021

Journal Articles

Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma

Aditi Sharma, Abhinav Achreja, Remya Nair, Pulkit Gupta, Claudia L Edgar, Olamide Animasahun, Anjali Mittal, Bhakti Dwivedi, Manoj Bhasin, Vikas A Gupta, Benjamin G Barwick, Shannon M Matulis, Sagar Lonial, Lawrence H. Boise, David L Jaye, Arun P Wiita, Ajay K. Nooka, Deepak Nagrath, Mala Shanmugam

Blood (2021) 138 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2021-153744

Published: 2021

Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-138869

Published: 2020

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Matthew Nix, PhD, Yu-Hsiu T. Lin, BA, Huimin Geng, PhD, Makeba Marcoulis, BA, Paul Phojanakong, BA, Donghui Wang, BA, Veronica Steri, PhD, Jeffrey Whitman, MD, Sagar Bapat, MD PhD, Elliot Stieglitz, MD, Anne Deucher, MD PhD, Kristie L White, MD MD, Byron C Hann, MD PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1337.

https://doi.org/10.1182/blood-2019-130938

Published: 2019

Journal Articles

Novel Allosteric Inhibitors of Heat Shock Protein 70 As Agents to Probe Protein Homeostasis and Overcome Proteasome Inhibitor Resistance in Multiple Myeloma

Ian Ferguson, BA, Christine Lam, BA, Margarette C. Mariano, MS, Donghui Wang, BA, Paul Phojanakong, BA, Sami Toumivaara, PhD, Hao Shao, PhD, Byron C Hann, MD PhD, Jason Gestwicki, PhD, Arun P Wiita, MDPhD

Blood (2018) 132 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2018-99-117401

Published: 2018

Journal Articles

Identifying Factors in Multiple Myeloma Controlling Response to B-Cell Maturation Antigen (BCMA)-Targeted Immunotherapy Using CRISPR-Based Functional Genomics

Poornima Ramkumar, PhD, Jaime Leong, B.S., Meghan Seyler, B.S., Stratton J Georgoulis, Axel Hyrenius Wittsten, PhD, Priya Choudhry, PhD, Kole Roybal, PhD, Arun P Wiita, MD PhD, Martin Kampmann, PhD

Blood (2018) 132 (Supplement 1): 1926.

https://doi.org/10.1182/blood-2018-99-115368

Published: 2018

Journal Articles

Integrating Phosphoproteomics and Transcriptional Classifiers Reveals "Hidden Signaling" in Multiple Myeloma Including Differential KRAS and NRAS Mutant Effects

Yu-Hsiu T. Lin, BA, Gergory P. Way, PhD, Margarette C. Mariano, MS, Makeba Marcoulis, BA, Ian Ferguson, BA, Casey S. Greene, PhD, Arun P Wiita, MD, PhD

Blood (2018) 132 (Supplement 1): 469.

https://doi.org/10.1182/blood-2018-99-113683

Published: 2018

Journal Articles

DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma

Priya Choudhry, PhD, Margarette C. Mariano, MS, Arun P Wiita, MD PhD

Blood (2018) 132 (Supplement 1): 5618.

https://doi.org/10.1182/blood-2018-99-114206

Published: 2018

Journal Articles

IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation

Jae-Woong Lee, PhD, Huimin Geng, PhD, Derek S Dinson, Gang Xiao, PhD, Kadriye Nehir Cosgun, PhD, Lai N Chan, Zhengshan Chen, MDPhD, Michael Farzan, MDPhD, Jae U Jung, PhD, Arun P Wiita, MDPhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 552.

https://doi.org/10.1182/blood-2018-99-117472

Published: 2018

Journal Articles

Defining the Cell Surface Proteome of MLL Rearranged Leukemia

Matthew Nix, PhD, Arun P. Wiita, MD PhD

Blood (2017) 130 (Supplement 1): 3971.

https://doi.org/10.1182/blood.V130.Suppl_1.3971.3971

Published: 2017

Journal Articles

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

Millicent Embry, Xiaofan Li, PhD, Abigail Yu, PhD, Cristina Abrahams, PhD, Nancy Y. Greenland, MD PhD, Kwun Wah Wen, MD PhD, Chris Jones, Venita DeAlmeida, PhD, Stellanie Krimm, Sarah Krueger, PhD, Shannon Matheny, PhD, Toni Kline, PhD, Alice Yam, PhD, Ryan Stafford, PhD, Arun P. Wiita, MD PhD, Trevor Hallam, PhD, Mark Lupher, PhD, Arturo Molina, MDMS, FACP

Blood (2017) 130 (Supplement 1): 4420.

https://doi.org/10.1182/blood.V130.Suppl_1.4420.4420

Published: 2017

NARROW

Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CD72 Nanobody-Based CAR-T Cells Have Potent Anti-Tumor Efficacy in B Cell Malignancies

Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma

Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Novel Allosteric Inhibitors of Heat Shock Protein 70 As Agents to Probe Protein Homeostasis and Overcome Proteasome Inhibitor Resistance in Multiple Myeloma

Identifying Factors in Multiple Myeloma Controlling Response to B-Cell Maturation Antigen (BCMA)-Targeted Immunotherapy Using CRISPR-Based Functional Genomics

Integrating Phosphoproteomics and Transcriptional Classifiers Reveals "Hidden Signaling" in Multiple Myeloma Including Differential KRAS and NRAS Mutant Effects

DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma

IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation

Defining the Cell Surface Proteome of MLL Rearranged Leukemia

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SΤRO-001

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only